Vincerx Pharma, Inc. Common Stock Cash Flow-to-Debt Ratio
Vincerx Pharma, Inc. Common Stock cash flow-to-debt ratio. Vincerx Pharma, Inc. Common Stock (VINC) has a Cash Flow-to-Debt Ratio of -1.70x as of March 2025, meaning its operating cash flow of $-4.45 Million could theoretically repay -2% of its total liabilities ($2.62 Million) in one year. See VINC financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Vincerx Pharma, Inc. Common Stock (2019–2024)
Cash flow-to-debt ratio of Vincerx Pharma, Inc. Common Stock from 2019 to 2024. Historical debt coverage capacity for Vincerx Pharma, Inc. Common Stock across 6 annual periods. Also explore Vincerx Pharma, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.
Vincerx Pharma, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2019–2024)
Vincerx Pharma, Inc. Common Stock cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Vincerx Pharma, Inc. Common Stock. For the full cash flow conversion analysis, see VINC operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -4.95x | $-26.13 Million | $5.28 Million | ▲ +14.5% |
| 2023 | -5.78x | $-40.45 Million | $7.00 Million | ▼ -12.7% |
| 2022 | -5.13x | $-59.60 Million | $11.62 Million | ▼ -166.6% |
| 2021 | -1.92x | $-33.40 Million | $17.36 Million | ▼ -364.9% |
| 2020 | -0.41x | $-2.28 Million | $5.50 Million | ▲ +48.0% |
| 2019 | -0.80x | $-35.00K | $44.00K | — |